Related Experiment Video
Updated: Aug 12, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
Published on: September 11, 2019
Hepatitis C infection in potential recipients with normal liver biochemistry does not preclude renal transplantation
Insights
Hepatitis C virus (HCV) infection is prevalent in renal transplant recipients, potentially causing chronic liver disease. While no HCV-positive patients died from liver failure, the virus may contribute to chronic hepatitis in this population.
Area of Science:
- Nephrology
- Hepatology
- Virology
Background:
- Renal transplant recipients are susceptible to various infections.
- The role of hepatitis C virus (HCV) in chronic liver disease among transplant patients requires further investigation.
Purpose of the Study:
- To determine the incidence and outcomes of HCV infection in renal transplant recipients and hemodialysis patients.
- To assess the association between HCV and chronic liver disease in these patient groups.
Main Methods:
- Retrospective study of 252 renal transplant recipients and 58 hemodialysis patients.
- Sera tested for HCV antibodies using enzyme immunoassays (second and first generation).
- Liver biochemistry, disease progression, and patient survival were monitored.
Main Results:
- HCV positivity was 15% in transplant recipients and 5% in hemodialysis patients.
- Overt liver disease occurred in 8.7% of transplant recipients, with 36% of these being HCV positive.
- No HCV-positive patients died of liver failure; however, chronic active hepatitis (CAH) was observed in HCV-positive and negative transplant patients.
Conclusions:
- Hepatitis C virus may be a significant cause of chronic hepatitis in renal transplant recipients.
- While HCV did not lead to fatal liver failure in this cohort, its contribution to chronic liver disease warrants attention.
- Hemodialysis patients showed no evidence of chronic liver disease, irrespective of HCV status.
Abstract:
The hepatitis C virus (HCV) may be an important cause of chronic liver disease in renal transplant recipients. We investigated retrospectively the incidence and outcome of HCV infection in long-term renal transplant recipients and patients on hemodialysis. Stored, pretransplant sera of transplant recipients with normal liver biochemistry at surgery were tested for hepatitis C by a second-generation enzyme immunoassay. Hemodialysis patients were tested by a first-generation enzyme-linked immunosorbent assay (ELISA) against c100-3. We studied 252 renal transplant recipients and 58 hemodialysis patients followed for 65 +/- 10 months and 26 +/- 6 months, respectively. Fifteen percent (38/252) of the transplant recipients were HCV positive as were 3/58 (5%) of the hemodialysis patients. Overt liver disease occurred in 22/252 (8.7%) transplant recipients and none in the hemodialysis group. Thirty-six percent (8/22) of transplant recipients with overt liver disease were HCV positive. No HCV-positive patients died of liver failure. Of six biopsies in the HCV-positive transplant group, two had histological evidence of CAH. CAH was seen in six of eight biopsies in the HCV-negative transplants and two of these latter patients progressed to cirrhosis. No hemodialysis patients had clinical or histological evidence of chronic liver disease. Two HCV-negative transplant patients died of liver failure, while no deaths related to liver disease occurred in hemodialysis patients regardless of HCV status. We conclude that hepatitis C may cause chronic hepatitis in renal transplant patients.(ABSTRACT TRUNCATED AT 250 WORDS)
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Hepatitis

